Roche,set to establish a Korean precision medical ecosystem

Along with four organizations such as the KSMO and the NCC

It will build a customized treatment platform by collecting data on cancer patients

Roche Korea announced on the 7th that it has signed term sheet with the KSMO to form a partnership with four organizations, including the KCSG, NCC, and the KHIDI, to establish a Korean precision medical ecosystem.

 

Turnsheet is the process of specifying and agreeing on major contract conditions such as goals, scope of cooperation, roles and responsibilities by institution prior to partnership contracts.

 

It is an extension of the Memorandum of Understanding (MOU) signed by these institutions and companies earlier.

 

With the signing of termsheet, they plan to conduct KOSMOS II, an expanded study of the KOSMOS Study on genomic mutation-based customized drug therapy for patients with advanced solid cancer, which began in 2020.

 

KOSMOS II is a study for the development of personalized cancer treatment, and aims to evaluate the effectiveness and stability of drugs and create a treatment platform tailored to genetic mutations by collecting NGS-based genetic test results and real world data for mid- to long-term clinical studies.

 

Through this study, the government plans to improve patient access to genome-based customized treatment, collect and integrate genetic data and clinical data of 1,000 cancer patients to establish a national "public clinical genome database" that can be used for new drug development.

 

The KSMO and the KCSG design KOSMOS II studies, provide customized treatment according to the results of the "Molecular Oncology Board (MTB)" and establish an actual clinical genome database.

 

MTB is a multidisciplinary expert consultative body that recommends optimal customized treatment policies for patients by interpreting genetic test results.

 

Society and research associations have already issued MTB treatment recommendations in December and provided customized treatment to about 100 patients in accordance with the guidelines.

 

As a national cancer data center designated by the MOHW, the NCC provides the technology and infrastructure necessary for the development of the first clinical genome database.

 

The KHIDI promotes cooperation with the MOHW and supports the recruitment of domestic and foreign pharmaceutical companies to participate in clinical research partnerships.

 

Multinational pharmaceutical companies, including Roche Korea, provide research medicines and other services for patients registered in the KOSMOS II study.

 

Meanwhile, the KSMO, the KCSG and Roche Korea signed an MOU to establish a Korean precision medical ecosystem in November 2019, strengthening the experience and expertise of domestic medical staff based on ▲ comprehensive genetic profiling and genetic tumor boards, ▲ deriving a plan to provide customized treatment for cancer patients who no longer have standard treatment options, ▲ establishment of a database within the scope of related laws and regulations in Korea, ▲ the government, academia, and pharmaceutical companies have cooperated to expand partnerships to establish a precision medical ecosystem.